Clonal Structure of Rapid-Onset MDV-Driven CD4+ Lymphomas and Responding CD8+ T Cells

PLoS Pathogens

Volumn 7, Issue 5, 2011, Pages

  Mwangi, William N ^a   Smith, Lorraine P ^a   Baigent, Susan J ^a   Beal, Richard K ^a   Nair, Venugopal ^a   Smith, Adrian L ^a,b  

^a INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR BETA CHAIN; ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIRD; BLOOD; CD4+ LYMPHOMA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CLONAL VARIATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LYMPHOMA; MARDIVIRUS; METASTASIS; MOLECULAR RECOGNITION; NONHUMAN; POULTRY; TUMOR LOCALIZATION; ANIMAL; CHICKEN; COMPLEMENTARITY DETERMINING REGION; GENETICS; IMMUNE SYSTEM; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MAREK DISEASE; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOGENICITY; PATHOLOGY; TUMOR CELL LINE; VIROLOGY;

AVES; GALLID HERPESVIRUS 2; HERPESVIRIDAE; HUMAN T-LYMPHOTROPIC VIRUS 1;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CHICKENS; COMPLEMENTARITY DETERMINING REGIONS; HERPESVIRUS 2, GALLID; IMMUNE SYSTEM; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOMA; MAREK DISEASE; MOLECULAR SEQUENCE DATA; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA;

EID: 79958059864     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1001337     Document Type: Article

References (81)

1. Epstein MA, (2001) Historical background. Philos Trans R Soc Lond B Biol Sci 356: 413-420.
2. Young LS, Rickinson AB, (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-768.
3. Ishitsuka K, Tamura K, (2008) Treatment of adult T-cell leukemia/lymphoma: past, present, and future. Eur J Haematol 80: 185-196.
4. Morrow CaFF, (2004) Marek's disease:a worldwide problem. In: Davison TF, Nair V, editors. Marek's disease An evolving Problem London Elsevier Academic Press pp. 49-61.
5. Burgess SC, Young JR, Baaten BJ, Hunt L, Ross LN, et al. (2004) Marek's disease is a natural model for lymphomas overexpressing Hodgkin's disease antigen (CD30). Proc Natl Acad Sci U S A 101: 13879-13884.
6. Schat KA, (1987) Marek's disease: a model for protection against herpesvirus-induced tumours. Cancer Surv 6: 1-37.
7. Weiss RA, (1998) The oncologist's debt to the chicken. Avian Pathology 27: S8-S15.
8. Calnek BW, (1986) Marek's disease-a model for herpesvirus oncology. Crit Rev Microbiol 12: 293-320.
9. Burgess SC, Basaran BH, Davison TF, (2001) Resistance to Marek's disease herpesvirus-induced lymphoma is multiphasic and dependent on host genotype. Vet Pathol 38: 129-142.
10. Burgess SC, Davison TF, (2002) Identification of the neoplastically transformed cells in Marek's disease herpesvirus-induced lymphomas: recognition by the monoclonal antibody AV37. J Virol 76: 7276-7292.
11. Nazerian K, Sharma JM, (1975) Detection of T-cell surface antigens in a Marek's disease lymphoblastoid cell line. J Natl Cancer Inst 54: 277-279.
12. Parcells MS, Dienglewicz RL, Anderson AS, Morgan RW, (1999) Recombinant Marek's disease virus (MDV)-derived lymphoblastoid cell lines: regulation of a marker gene within the context of the MDV genome. J Virol 73: 1362-1373.
13. Schat KA, Chen CL, Calnek BW, Char D, (1991) Transformation of T-lymphocyte subsets by Marek's disease herpesvirus. J Virol 65: 1408-1413.
14. Schat KA, Chen CL, Shek WR, Calnek BW, (1982) Surface antigens on Marek's disease lymphoblastoid tumor cell lines. J Natl Cancer Inst 69: 715-720.
15. Brown AC, Baigent SJ, Smith LP, Chattoo JP, Petherbridge LJ, et al. (2006) Interaction of MEQ protein and C-terminal-binding protein is critical for induction of lymphomas by Marek's disease virus. Proc Natl Acad Sci U S A 103: 1687-1692.
16. Ross N, O'Sullivan G, Rothwell C, Smith G, Burgess SC, et al. (1997) Marek's disease virus EcoRI-Q gene (meq) and a small RNA antisense to ICP4 are abundantly expressed in CD4+ cells and cells carrying a novel lymphoid marker, AV37, in Marek's disease lymphomas. J Gen Virol 78 (Pt 9): 2191-2198.
17. Xie Q, Anderson AS, Morgan RW, (1996) Marek's disease virus (MDV) ICP4, pp38, and meq genes are involved in the maintenance of transformation of MDCC-MSB1 MDV-transformed lymphoblastoid cells. J Virol 70: 1125-1131.
18. Delecluse HJ, Hammerschmidt W, (1993) Status of Marek's disease virus in established lymphoma cell lines: herpesvirus integration is common. J Virol 67: 82-92.
19. Delecluse HJ, Schuller S, Hammerschmidt W, (1993) Latent Marek's disease virus can be activated from its chromosomally integrated state in herpesvirus-transformed lymphoma cells. EMBO J 12: 3277-3286.
20. Bublot MaSJ, (2004) Vaccination against Marek's disease. In: Davison TF, Nair V, editors. Marek's disease An evolving Problem London Elsevier Academic Press pp. 168-182.
21. Davison F, Nair V, (2005) Use of Marek's disease vaccines: could they be driving the virus to increasing virulence? Expert Rev Vaccines 4: 77-88.
22. Witter RL, (1998) Control strategies for Marek's disease: a perspective for the future. Poult Sci 77: 1197-1203.
23. Morimura T, Ohashi K, Sugimoto C, Onuma M, (1998) Pathogenesis of Marek's disease (MD) and possible mechanisms of immunity induced by MD vaccine. J Vet Med Sci 60: 1-8.
24. Wu C, Gan J, Jin Q, Chen C, Liang P, et al. (2009) Revaccination with Marek's disease vaccines induces productive infection and superior immunity. Clin Vaccine Immunol 16: 184-193.
25. Bacon LD, Crittenden LB, Witter RL, Fadly A, Motta J, (1983) B5 and B15 associated with progressive Marek's disease, Rous sarcoma, and avian leukosis virus-induced tumors in inbred 15I4 chickens. Poult Sci 62: 573-578.
26. Bacon LD, Witter RL, (1993) Influence of B-haplotype on the relative efficacy of Marek's disease vaccines of different serotypes. Avian Dis 37: 53-59.
27. Bacon LD, Witter RL, (1994) B haplotype influence on the relative efficacy of Marek's disease vaccines in commercial chickens. Poult Sci 73: 481-487.
28. Bacon LD, Witter RL, Crittenden LB, Fadly A, Motta J, (1981) B-haplotype influence on Marek's disease, Rous sarcoma, and lymphoid leukosis virus-induced tumors in chickens. Poult Sci 60: 1132-1139.
29. Briles WE, Briles RW, Taffs RE, Stone HA, (1983) Resistance to a malignant lymphoma in chickens is mapped to subregion of major histocompatibility (B) complex. Science 219: 977-979.
30. Buscaglia C, Calnek BW, (1988) Maintenance of Marek's disease herpesvirus latency in vitro by a factor found in conditioned medium. J Gen Virol 69 (Pt 11): 2809-2818.
31. Kaiser P, Underwood G, Davison F, (2003) Differential cytokine responses following Marek's disease virus infection of chickens differing in resistance to Marek's disease. J Virol 77: 762-768.
32. Levy AM, Heller ED, Leitner G, Davidson I, (1999) Effect of native chicken interferon on MDV replication. Acta Virol 43: 121-127.
33. Volpini LM, Calnek BW, Sekellick MJ, Marcus PI, (1995) Stages of Marek's disease virus latency defined by variable sensitivity to interferon modulation of viral antigen expression. Vet Microbiol 47: 99-109.
34. Xing Z, Schat KA, (2000) Expression of cytokine genes in Marek's disease virus-infected chickens and chicken embryo fibroblast cultures. Immunology 100: 70-76.
35. Schat KA, (1991) Importance of cell-mediated immunity in Marek's disease and other viral tumor diseases. Poult Sci 70: 1165-1175.
36. Schat KA, Markowski-Grimsrud CJ, (2001) Immune responses to Marek's disease virus infection. Curr Top Microbiol Immunol 255: 91-120.
37. Markowski-Grimsrud CJ, Schat KA, (2002) Cytotoxic T lymphocyte responses to Marek's disease herpesvirus-encoded glycoproteins. Vet Immunol Immunopathol 90: 133-144.
38. Omar AR, Schat KA, (1996) Syngeneic Marek's disease virus (MDV)-specific cell-mediated immune responses against immediate early, late, and unique MDV proteins. Virology 222: 87-99.
39. Omar AR, Schat KA, (1997) Characterization of Marek's disease herpesvirus-specific cytotoxic T lymphocytes in chickens inoculated with a non-oncogenic vaccine strain of MDV. Immunology 90: 579-585.
40. Morimura T, Cho KO, Kudo Y, Hiramoto Y, Ohashi K, et al. (1999) Anti-viral and anti-tumor effects induced by an attenuated Marek's disease virus in CD4- or CD8-deficient chickens. Arch Virol 144: 1809-1818.
41. Day EK, Carmichael AJ, ten Berge IJ, Waller EC, Sissons JG, et al. (2007) Rapid CD8+ T cell repertoire focusing and selection of high-affinity clones into memory following primary infection with a persistent human virus: human cytomegalovirus. J Immunol 179: 3203-3213.
42. Sacre K, Carcelain G, Cassoux N, Fillet AM, Costagliola D, et al. (2005) Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med 201: 1999-2010.
43. Callan MF, Tan L, Annels N, Ogg GS, Wilson JD, et al. (1998) Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med 187: 1395-1402.
44. Hislop AD, Ressing ME, van Leeuwen D, Pudney VA, Horst D, et al. (2007) A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 204: 1863-1873.
45. Mwangi WN, Beal RK, Powers C, Wu X, Humphrey T, et al. (2010) Regional and global changes in TCRalphabeta T cell repertoires in the gut are dependent upon the complexity of the enteric microflora. Dev Comp Immunol 34: 406-417.
46. Cooper MD, Chen CL, Bucy RP, Thompson CB, (1991) Avian T cell ontogeny. Adv Immunol 50: 87-117.
47. McCormack WT, Tjoelker LW, Stella G, Postema CE, Thompson CB, (1991) Chicken T-cell receptor beta-chain diversity: an evolutionarily conserved D beta-encoded glycine turn within the hypervariable CDR3 domain. Proc Natl Acad Sci U S A 88: 7699-7703.
48. Shigeta A, Sato M, Kawashima T, Horiuchi H, Matsuda H, et al. (2004) Genomic organization of the chicken T-cell receptor beta chain D-J-C region. J Vet Med Sci 66: 1509-1515.
49. Tjoelker LW, Carlson LM, Lee K, Lahti J, McCormack WT, et al. (1990) Evolutionary conservation of antigen recognition: the chicken T-cell receptor beta chain. Proc Natl Acad Sci U S A 87: 7856-7860.
50. Schat KA, Calnek BW, Fabricant J, (1982) Characterisation of two highly oncogenic strains of Marek's disease virus. Avian Pathol 11: 593-605.
51. Petherbridge L, Brown AC, Baigent SJ, Howes K, Sacco MA, et al. (2004) Oncogenicity of virulent Marek's disease virus cloned as bacterial artificial chromosomes. J Virol 78: 13376-13380.
52. Petherbridge L, Howes K, Baigent SJ, Sacco MA, Evans S, et al. (2003) Replication-competent bacterial artificial chromosomes of Marek's disease virus: novel tools for generation of molecularly defined herpesvirus vaccines. J Virol 77: 8712-8718.
53. Chan MM, Chen CL, Ager LL, Cooper MD, (1988) Identification of the avian homologues of mammalian CD4 and CD8 antigens. J Immunol 140: 2133-2138.
54. Akiyama Y, Kato S, (1974) Scanning electron microscopy of lymphoid cell lines and lymphocytes from thymus, bursa and blood of chickens. Biken J 17: 193-197.
55. Nazerian K, Witter RL, (1975) Properties of a chicken lymphoblastoid cell line from Marek's disease tumor. J Natl Cancer Inst 54: 453-458.
56. Payne LN, Howes K, Rennie M, Bumstead JM, Kidd AW, (1981) Use of an agar culture technique for establishing lymphoid cell lines from Marek's disease lymphomas. Int J Cancer 28: 757-766.
57. Nazerian K, Stephens EA, Sharma JM, Lee LF, Gailitis M, et al. (1977) A nonproducer T lymphoblastoid cell line from Marek's disease transplantable tumor (JMV). Avian Dis 21: 69-76.
58. Yao Y, Zhao Y, Smith LP, Lawrie CH, Saunders NJ, et al. (2009) Differential expression of microRNAs in Marek's disease virus-transformed T-lymphoma cell lines. J Gen Virol 90: 1551-1559.
59. Yao Y, Zhao Y, Xu H, Smith LP, Lawrie CH, et al. (2008) MicroRNA profile of Marek's disease virus-transformed T-cell line MSB-1: predominance of virus-encoded microRNAs. J Virol 82: 4007-4015.
60. Dunon D, Schwager J, Dangy JP, Cooper MD, Imhof BA, (1994) T cell migration during development: homing is not related to TCR V beta 1 repertoire selection. EMBO J 13: 808-815.
61. Agresti A, Coull B, (1998) Approximate is better than 'exact' for interval estimation of binomial proportions. Am Stat 52: 119-126.
62. Nazerian K, (1987) An updated list of avian cell lines and transplantable tumours. Avian Pathol 16: 527-544.
63. Parvizi P, Read LR, Abdul-Careem MF, Sarson AJ, Lusty C, et al. (2009) Cytokine gene expression in splenic CD4+ and CD8+ T cell subsets of genetically resistant and susceptible chickens infected with Marek's disease virus. Vet Immunol Immunopathol 132: 209-217.
64. Callan MF, Annels N, Steven N, Tan L, Wilson J, et al. (1998) T cell selection during the evolution of CD8+ T cell memory in vivo. Eur J Immunol 28: 4382-4390.
65. Hislop AD, Taylor GS, Sauce D, Rickinson AB, (2007) Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25: 587-617.
66. Collette A, Cazenave PA, Pied S, Six A, (2003) New methods and software tools for high throughput CDR3 spectratyping. Application to T lymphocyte repertoire modifications during experimental malaria. J Immunol Methods 278: 105-116.
67. Kedzierska K, La Gruta NL, Stambas J, Turner SJ, Doherty PC, (2008) Tracking phenotypically and functionally distinct T cell subsets via T cell repertoire diversity. Mol Immunol 45: 607-618.
68. Long SA, Khalili J, Ashe J, Berenson R, Ferrand C, et al. (2006) Standardized analysis for the quantification of Vbeta CDR3 T-cell receptor diversity. J Immunol Methods 317: 100-113.
69. Ohshima K, Suzumiya J, Kato A, Tashiro K, Kikuchi M, (1997) Clonal HTLV-I-infected CD4+ T-lymphocytes and non-clonal non-HTLV-I-infected giant cells in incipient ATLL with Hodgkin-like histologic features. Int J Cancer 72: 592-598.
70. Okayama A, Stuver S, Matsuoka M, Ishizaki J, Tanaka G, et al. (2004) Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia/lymphoma in asymptomatic carriers. Int J Cancer 110: 621-625.
71. Parcells MS, Burgess SC, (2008) Immunolgical Aspects of Marek's Disease Virus (MDV)-Induced Lymphoma Progression. Selected Aspects of Cancer Progression: Metastasis, Apoptosis, and Immune Response pp. 169-191.
72. Parvizi P, Read L, Abdul-Careem MF, Lusty C, Sharif S, (2009) Cytokine gene expression in splenic CD4(+) and CD8(+) T-cell subsets of chickens infected with Marek's disease virus. Viral Immunol 22: 31-38.
73. Abdul-Careem MF, Hunter DB, Lambourne MD, Read LR, Parvizi P, et al. (2008) Expression of cytokine genes following pre- and post-hatch immunization of chickens with herpesvirus of turkeys. Vaccine 26: 2369-2377.
74. Abdul-Careem MF, Hunter DB, Shanmuganathan S, Haghighi HR, Read L, et al. (2008) Cellular and cytokine responses in feathers of chickens vaccinated against Marek's disease. Vet Immunol Immunopathol 126: 362-366.
75. Abdul-Careem MF, Hunter BD, Sarson AJ, Parvizi P, Haghighi HR, et al. (2008) Host responses are induced in feathers of chickens infected with Marek's disease virus. Virology 370: 323-332.
76. Kattan T, MacNamara A, Rowan AG, Nose H, Mosley AJ, et al. (2009) The avidity and lytic efficiency of the CTL response to HTLV-1. J Immunol 182: 5723-5729.
77. Moss P, Khan N, (2004) CD8(+) T-cell immunity to cytomegalovirus. Hum Immunol 65: 456-464.
78. Beverley PC, (2004) Kinetics and clonality of immunological memory in humans. Semin Immunol 16: 315-321.
79. van Stipdonk MJ, Lemmens EE, Schoenberger SP, (2001) Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2: 423-429.
80. Kaufman J, Milne S, Gobel TW, Walker BA, Jacob JP, et al. (1999) The chicken B locus is a minimal essential major histocompatibility complex. Nature 401: 923-925.
81. Venturi V, Price DA, Douek DC, Davenport MP, (2008) The molecular basis for public T-cell responses? Nat Rev Immunol 8: 231-238.